Aslan’s insiders
What Asian biotechs considering NASDAQ could learn from Aslan’s listing
A disappointing offering on NASDAQ by Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) looks to be the consequence of Taiwan exchange rules that prevented more robust insider participation. So even though big names such as Morningside and Temasek bought 60% of the deal, excluded insiders meant NASDAQ investors saw only that the overall insider stake
